Pharmacologic treatments for covid-19 patients

Canakinumab vs Placebo

On Jan 26th, 2022, we published results of the Are medicines that block interleukin‐1 (a protein involved in immune responses) effective treatments for COVID‐19 and do they cause unwanted effects? which included all preprints and published trials published online up to November 5, 2021.


Hospitalized patients

Forest plots
(last update: 2021-11-18)

Summary of findings
(last update: 2021-12-08)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=357

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04362813; EudraCT 2020-001370-30
CAN-COVID
Caricchio R, JAMA, 2021
Full text
Commentary
Private

Canakinumab

Placebo

RCT Patients with suspected or confirmed COVID-19 (mild-severe) admitted to 39 centers in France, Italy, Russia, Spain, UK and USA. N=454
Low
Details

Full description

NCT04365153
The three C study
Cremer P, Eur Heart J, 2021
Full text
Full text
Commentary
Private

Canakinumab 600

Canakinumab 300

Canakinumab 600

Placebo

Placebo

Canakinumab 300

RCT Patients with confirmed COVID-19 (mild-critical) admitted to 2 centers in the USA N=45
Some concerns
Details

Full description